Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent recombinant norovirus vaccine
- Development stage
- Unknown
- Lead developer
- Grand-Sevax Life Sciences
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent recombinant norovirus vaccine is a virus-like particle (VLP) vaccine developed by Grand Sevax Life Sciences (a subsidiary of Grand Pharma). It is produced using a *Hansenula polymorpha* (Hansen yeast) expression system and targets four major norovirus genotypes: GII.2, GII.4, GII.6, and GII.17. The vaccine is composed of recombinant VP1 capsid proteins from these genotypes, which self-assemble into non-infectious VLPs that mimic the structure of the native virus to elicit a protective immune response. It is currently being evaluated in Phase 1 clinical trials in China for the prevention of acute gastroenteritis caused by norovirus infection in individuals aged 6 months and older.
- Other names
- Quadrivalent recombinant norovirus vaccine (Hansen yeast)四价重组诺如病毒疫苗（汉逊酵母）
02
Targets
Norovirus VP1BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on quadrivalent recombinant norovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent recombinant norovirus vaccine.